Published in Gene Therapy Weekly, April 29th, 2004
"Previous research has indicated that we may be able to promote selective destruction of tumor cells while minimizing the damage to normal cells using EphA2 antibodies," said Peter Kiener, DPhil, vice president, research at MedImmune. "These new data reveal that we also may one day apply new bacteria-mediated strategies for treating or preventing the many cancers that express the EphA2 protein, including breast and colon cancer."
To evaluate the effects of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.